The promise of widespread access to the cell & gene therapies hinges on the industry’s ability to bring them to market. Even as the patient demand grows, therapy developers today are burdened with increasing cost pressures. Understanding the total cost of ownership (TCO) is now critical to navigating the transition from early development to commercial manufacturing.

In this webinar, experts from Kincell Bio, Adaptimmune, and Oribiotech will explore the financial and operational realities therapy developers face as they transition from preclinical to commercial manufacturing.

What you’ll learn:

• The hidden costs that often go unaccounted for in early tech decisions
• How early decisions around process design can shape or strain commercial scale-up
• Practical trade-offs between automation, flexibility, and platform integration
• How to evaluate and manage total cost of ownership (TCO) across clinical and commercial stages

Whether you’re preparing your first IND or planning for commercial launch, this webinar will help you build a strategy that’s scientifically sound and economically sustainable.